Stay updated on Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial page.
Latest updates to the Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe website has been updated from version 2.9.7 to 2.10.0, indicating a new release with potential enhancements or features.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Not provided' for the Progression Free Survival [Time Frame: 16 Week] has been updated to '(Submitted: 2017-10-06)' which indicates a recent submission and change in the data for this specific outcome measure in the study evaluating Neratinib versus Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer.SummaryDifference4%
Stay in the know with updates to Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial page.